More data for two-dose regimen of GSK's HPV vaccine

Researchers at NIH's National Cancer Institute and colleagues reported data from the Phase III CVT trial in females aged 18-25 that they said raise the possibility that even a single dose of HPV vaccine Cervarix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will induce long-term protection against HPV infection. In the trial, a two-dose schedule of Cervarix administered at zero and six months led to HPV types 16 and 18 geometric mean titers (GMTs) at four years that were non-inferior to a three-dose schedule of Cervarix administered at zero, one and six months. Additionally, a single dose of Cervarix led to an HPV type 16 GMT that was 9.4 times greater and an HPV type 18 GMT that was 4.8 times greater at four years compared to a subgroup of women who were HPV type 16 or 18-seropositive prior to vaccination, presumably from natural infection. Antibody levels following a single dose of Cervarix remained stable from six months post-vaccination through four years. Data were published in Cancer Prevention Research.

Separately, GSK said in the Phase IIIb HPV-070 trial that a two-dose schedule of Cervarix administered at zero and six months in females aged 9-14 induced immune responses that were "comparable" to that of a three-dose schedule of Cervarix administered at zero, one and six months in females aged 15-25. Data were presented at the EUROGIN meeting in Florence. ...